Table 1 Clinical data.
From: FGF Signalling in the Self-Renewal of Colon Cancer Organoids
ID | Gender | Age | Location sampled tissue | UICC | Primary Tumour (TNM) | Differentiation | Pre-treatment | BRAF/NRAS/KRAS |
|---|---|---|---|---|---|---|---|---|
Patient 1 | M | 62 | Liver | IV | pT2 pN1 M1hep | Moderate | 5-FU, Oxaliplatin, Bevacizumab | wt/wt/G12D |
Patient 2 | M | 64 | para rectal LN | IV | pT2 pN2 M1hep | Moderate | 5-FU, Oxaliplatin, Cetuximab | wt/wt/wt |
Patient 3 | F | 81 | Sigmoid | IV | pT3 pN1 M1hep | Moderate | / | wt/G12V/wt |
Patient 4 | M | 51 | Sigmoid | IB | pT2 pN0 M0 | Poor | / | wt/G12S/wt |
Patient 5 | F | 59 | Rectum | IB | pT2 pN0 M0 | Well | Capecitabine, Radiotherapy (50,4 Gy) | |
Patient 6 | F | 58 | Rectum | HGIEN | / | |||
Patient 7 | F | 85 | Rectum | IIA | pT3 pN0 M0 | Well | / | |
Patient 8 | M | 74 | Liver | IV | pT2 pN0 M1hep | Moderate | / | |
Patient 9 | M | 75 | Sigmoid | IIA | pT3 pN0 M0 | Well | / |
